Financings

Akebia Therapeutics Inc. raised $22 million in a Series B round.

Cell Therapeutics Inc. is raising $16 million in a preferred stock and warrant sale.

Oxford Nanopore Ltd. brought in $41.2 million in its fourth private round.

Deals

Karo Bio AB signed an Indian licensing and collaboration agreement with Alkem Laboratories Ltd. for lipid-lowering candidate eprotirome.

Kuros Biosurgery AG said partner Baxter International Inc. bailed on three more programs, leaving just one, KUR-211, in diabetic foot ulcers.

Sequella Inc. inked a deal valued at about $50 million for tuberculosis drug SQ109 with the Maxwell Biotech Venture Fund.

. . . And More

Allergy Therapeutics plc said the FDA lifted the clinical hold on its allergy vaccines.

Columbia Laboratories Inc. submitted a new drug application for Prochieve (progesterone gel) for the reduction of preterm birth.

Endocyte Inc.'s stock jumped 25 percent on news that it would seek European approval for ovarian cancer candidate EC145 and its companion diagnostic.

Millennium Pharmaceuticals Inc., a Takeda subsidiary, submitted two supplemental new drug applications for Velcade (bortezomib).

Regeneron Pharmaceuticals Inc.'s Zalrep (aflibercept) hit its endpoint in a Phase III metastatic colon cancer study.